NCT04630613Recruiting
NOX4 and Related Biomarkers in ADPKD
NOX4, Mitochondria and Related Biomarkers in Autosomal Dominant Polycystic Kidney Disease
Source: ClinicalTrials.gov · Last updated 9 Jan 2026
Brief summary (registry, in English)
To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 10 Nov 2020
- Start date
- 21 Jul 2020
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Mayo Clinic
- Diseases
- Polycystic kidney disease
- NCT number
- NCT04630613
What you commit to
- Study type: Observational
- Planned participants: 60
- From 21 Jul 2020 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant systemic disease affecting the kidney
Other illness
- Diabetes mellitus
Other
- Class 2 according to imaging classification
- Predicted urine protein excretion in \>1 g/24 hrs
- Use of antioxidants i.e. vitamins, Nrf2 activators
- Abnormal urinalysis
Who the study is looking for
- ADPKD (based on Ravine et al. criteria)
- Class 1 A-E according to imaging classification
- Male and female subjects 15 - 40 years of age
- Estimated GFR\> 70 mL/min/1.73 m2 (CKD-EPI)
- Ability to provide written, informed consent
Age in the registry: 15 years to 40 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.